PharmAthene anthrax vax aces survival in rabbit study

New Zealand white rabbit

PharmAthene's ($PIP) anthrax vaccine candidate, SparVax, works at least as well as currently licensed BioThrax from Emergent BioSolutions ($EBS)--at least, according to a study in New Zealand white rabbits. After receiving SparVax, the rabbits demonstrated 100% survival of a lethal dose of aerosolized anthrax spores, with antibody titers for SparVax up to two-fold higher than BioThrax, PharmAthene said. "One of the requirements for licensure of rPA vaccines is equivalency relative to the current vaccine, so we are encouraged by these results," CEO Eric Richman said in a statement. Release

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.